JP2019532933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532933A5 JP2019532933A5 JP2019515834A JP2019515834A JP2019532933A5 JP 2019532933 A5 JP2019532933 A5 JP 2019532933A5 JP 2019515834 A JP2019515834 A JP 2019515834A JP 2019515834 A JP2019515834 A JP 2019515834A JP 2019532933 A5 JP2019532933 A5 JP 2019532933A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- motomeko
- subject
- aom
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 claims description 152
- 210000001519 tissue Anatomy 0.000 claims description 28
- 230000004968 inflammatory condition Effects 0.000 claims description 17
- 210000003928 nasal cavity Anatomy 0.000 claims description 17
- 206010020772 Hypertension Diseases 0.000 claims description 16
- 208000012902 Nervous system disease Diseases 0.000 claims description 16
- 208000026344 Nasal disease Diseases 0.000 claims description 15
- 208000030880 Nose disease Diseases 0.000 claims description 15
- 208000018920 Paranasal Sinus disease Diseases 0.000 claims description 15
- 208000028347 Sinus disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 9
- 206010019233 Headaches Diseases 0.000 claims description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- 231100000869 headache Toxicity 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 8
- 230000009885 systemic effect Effects 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 6
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 6
- 239000012062 aqueous buffer Substances 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 201000011461 pre-eclampsia Diseases 0.000 claims description 6
- 230000035935 pregnancy Effects 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 241001495394 Nitrosospira Species 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
- 235000019800 disodium phosphate Nutrition 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010019663 Hepatic failure Diseases 0.000 claims description 3
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 claims description 3
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 241000605122 Nitrosomonas Species 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 230000005961 cardioprotection Effects 0.000 claims description 3
- 208000027744 congestion Diseases 0.000 claims description 3
- 208000018631 connective tissue disease Diseases 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 208000007903 liver failure Diseases 0.000 claims description 3
- 231100000835 liver failure Toxicity 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 230000028624 response to insect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 208000030954 urea cycle disease Diseases 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 241000192147 Nitrosococcus Species 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 238000009792 diffusion process Methods 0.000 claims description 2
- -1 e.g. Substances 0.000 claims description 2
- 210000000750 endocrine system Anatomy 0.000 claims description 2
- 230000008753 endothelial function Effects 0.000 claims description 2
- 238000013265 extended release Methods 0.000 claims description 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 230000028709 inflammatory response Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 206010041232 sneezing Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000008718 systemic inflammatory response Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 241001453382 Nitrosomonadales Species 0.000 claims 2
- 241000605120 Nitrosomonas eutropha Species 0.000 claims 2
- 241000192123 Nitrosovibrio Species 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
- 229940100662 nasal drops Drugs 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 125
- 210000001944 turbinate Anatomy 0.000 description 6
- 206010040744 Sinus headache Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002530 ischemic preconditioning effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003273 vestibular nerve Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662397642P | 2016-09-21 | 2016-09-21 | |
| US62/397,642 | 2016-09-21 | ||
| PCT/US2017/052671 WO2018057710A1 (en) | 2016-09-21 | 2017-09-21 | Ammonia oxidizing microorganisms for use and delivery to the intranasal system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532933A JP2019532933A (ja) | 2019-11-14 |
| JP2019532933A5 true JP2019532933A5 (https=) | 2020-11-12 |
Family
ID=60022194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515834A Pending JP2019532933A (ja) | 2016-09-21 | 2017-09-21 | 鼻腔内系への使用および送達のためのアンモニア酸化微生物 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20200016216A1 (https=) |
| EP (1) | EP3515464B1 (https=) |
| JP (1) | JP2019532933A (https=) |
| KR (1) | KR20190055159A (https=) |
| CN (1) | CN110191716A (https=) |
| AU (1) | AU2017332347A1 (https=) |
| BR (1) | BR112019005536A2 (https=) |
| CA (1) | CA3037703A1 (https=) |
| IL (1) | IL265508A (https=) |
| MX (1) | MX2019003191A (https=) |
| PH (1) | PH12019500622A1 (https=) |
| RU (1) | RU2019111715A (https=) |
| SG (1) | SG10202109410XA (https=) |
| WO (1) | WO2018057710A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210100224A (ko) * | 2014-04-15 | 2021-08-13 | 에이오바이오미 엘엘씨 | 암모니아-산화 니트로소모나스 유트로파 균주 d23 |
| WO2019018425A1 (en) * | 2017-07-18 | 2019-01-24 | Aobiome Llc | AMMONIA-OXIDIZING MICROORGANISMS FOR INJECTION USE AND ADMINISTRATION |
| WO2019018348A1 (en) * | 2017-07-18 | 2019-01-24 | Aobiome Llc | AMMONIA-OXIDIZING MICROORGANISMS FOR UTILIZATION AND ADMINISTRATION AT THE UROGENITAL SYSTEM |
| US20200206278A1 (en) * | 2017-07-18 | 2020-07-02 | Aobiome Llc | Ammonia oxidizing microorganisms for the treatment of pulmonary hypertension |
| EP3654999A4 (en) * | 2017-07-18 | 2021-03-31 | Aobiome LLC | AMMONIA COXIDIZING MICROORGANISMS FOR THE TREATMENT OF HEADACHE |
| US10883260B2 (en) * | 2018-01-17 | 2021-01-05 | Andrew Lee Reger | Scent barrier and dispenser |
| KR102831159B1 (ko) | 2018-04-16 | 2025-07-07 | 온퀄리티 파마슈티컬스 차이나 리미티드 | 암 치료의 부작용을 예방하거나 치료하기 위한 방법 |
| WO2022147585A1 (en) * | 2020-12-31 | 2022-07-07 | Ntby Moss Llc | Formulations of a prophylactic nasal spray and methods of use and manufacture thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| FR2774674B1 (fr) | 1998-02-10 | 2000-03-24 | Atochem Elf Sa | Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre |
| KR20030065463A (ko) | 2000-08-11 | 2003-08-06 | 데이비드 알. 휘트록 | 질소 산화물 및 질소 산화물 전구체의 생산을 증가시키기위한 암모니아 산화 박테리아를 포함하는 조성물 및 이를이용하는 방법 |
| KR20210100224A (ko) * | 2014-04-15 | 2021-08-13 | 에이오바이오미 엘엘씨 | 암모니아-산화 니트로소모나스 유트로파 균주 d23 |
| US10383900B2 (en) * | 2014-05-22 | 2019-08-20 | Aobiome Llc | Systems and methods for storage and delivery of ammonia oxidizing bacteria |
| CA2949833C (en) | 2014-05-22 | 2024-06-11 | Aobiome Llc | Methods of preparing materials with ammonia oxidizing bacteria and testing materials for ammonia oxidizing bacteria |
| WO2016161285A1 (en) * | 2015-04-02 | 2016-10-06 | Aobiome Llc | Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria |
| CN109069878A (zh) | 2015-07-02 | 2018-12-21 | Ao生物医学有限责任公司 | 微生物群系相容性化妆品 |
| WO2017004557A1 (en) * | 2015-07-02 | 2017-01-05 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of acne |
-
2017
- 2017-09-21 BR BR112019005536A patent/BR112019005536A2/pt not_active Application Discontinuation
- 2017-09-21 CA CA3037703A patent/CA3037703A1/en active Pending
- 2017-09-21 KR KR1020197010958A patent/KR20190055159A/ko not_active Ceased
- 2017-09-21 MX MX2019003191A patent/MX2019003191A/es unknown
- 2017-09-21 SG SG10202109410X patent/SG10202109410XA/en unknown
- 2017-09-21 AU AU2017332347A patent/AU2017332347A1/en not_active Abandoned
- 2017-09-21 CN CN201780071609.XA patent/CN110191716A/zh active Pending
- 2017-09-21 EP EP17780585.0A patent/EP3515464B1/en active Active
- 2017-09-21 JP JP2019515834A patent/JP2019532933A/ja active Pending
- 2017-09-21 WO PCT/US2017/052671 patent/WO2018057710A1/en not_active Ceased
- 2017-09-21 RU RU2019111715A patent/RU2019111715A/ru unknown
- 2017-09-21 US US16/335,434 patent/US20200016216A1/en not_active Abandoned
-
2019
- 2019-03-20 IL IL265508A patent/IL265508A/en unknown
- 2019-03-21 PH PH12019500622A patent/PH12019500622A1/en unknown
-
2022
- 2022-07-15 US US17/812,889 patent/US20220347230A1/en not_active Abandoned
-
2023
- 2023-01-26 US US18/160,007 patent/US20230172998A1/en not_active Abandoned
- 2023-08-25 US US18/238,167 patent/US20230398157A1/en not_active Abandoned
-
2025
- 2025-04-10 US US19/175,409 patent/US20250235489A1/en not_active Abandoned
- 2025-11-13 US US19/388,926 patent/US20260069642A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532933A5 (https=) | ||
| RU2019111715A (ru) | Окисляющие аммиак микроорганизмы для применения и доставки в интраназальной системе | |
| DE69725160D1 (de) | Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten | |
| RU2005129267A (ru) | Препараты для чрескожной и чресслизистой доставки | |
| SE0000601D0 (sv) | Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet | |
| DE60119976D1 (en) | Thixotropes nasenspray | |
| KR102430892B1 (ko) | 비강 울혈을 치료/예방하기 위한 카르복실산 | |
| US20140377357A1 (en) | Poloxamer Based Inhalation Composition | |
| US20250325763A1 (en) | Devices for storage and delivery of nonpathogenic microorganisms | |
| Prulière-Escabasse et al. | Consensus document for prescription of nebulization in rhinology | |
| CN115708877B (zh) | 一种药物递送系统及其制备方法与应用 | |
| IL194346A0 (en) | Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application | |
| WO2023059716A8 (en) | Compositions and methods for levodopa delivery | |
| CN107049997A (zh) | 局部给药型的吞咽障碍改善用药物 | |
| JPH10130148A (ja) | ネブライザー用組成物 | |
| Petty | Pulmonary rehabilitation | |
| Crescimanno et al. | Successful treatment of atelectasis with Dornase alpha in a patient with congenital muscular dystrophy | |
| Mattingly et al. | Intermediate syndrome after exposure to chlorpyrifos in a 16-month-old girl | |
| Davis | INHALATION OF PENICILLIN AEROSOL AND PENICILLINSTREPTOMYCIN AEROSOL IN OFFICE PRACTICE | |
| Chandrasekaran et al. | Serratiopeptidase: a multifaceted microbial enzyme in health care | |
| CN113952365A (zh) | 一种局部用益生菌液处理慢性支气管炎的方法 | |
| AU723500B2 (en) | Caffeine composition as medicament and use thereof | |
| US20130336928A1 (en) | Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s) | |
| CN201194979Y (zh) | 氧气雾化吸入器固定带 | |
| RU2182005C2 (ru) | Способ лечения гриппа |